Revance Therapeutics. has filed a patent for a method using a neurotoxin to treat mood disorders, anxiety, and sleep disorders. The patent also includes a claim for treating migraines and accompanying sleep disorders with a botulinum toxin A-based pharmaceutical composition. GlobalData’s report on Revance Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Revance Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Revance Therapeutics's grant share as of January 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.
Treating migraine and sleep disorders with botulinum toxin
A patent application (Publication Number: US20240000906A1) describes a method for treating migraine in individuals with an accompanying sleep disorder by administering a pharmaceutical composition containing botulinum toxin A. The treatment aims to not only address the migraine but also reduce symptoms of the sleep disorder, specifically targeting delayed sleep phase disorder, advanced sleep phase disorder, or a combination of both. Additionally, the method accounts for subjects with atopic disease and those experiencing pain, particularly pain responsive to tactile stimulation, with the treatment resulting in pain relief.
Furthermore, the patent application extends the method to treat the repetitive occurrence of common migraine headaches in individuals with an accompanying sleep disorder. By administering the pharmaceutical composition containing botulinum toxin A, the treatment aims to address both the repetitive migraines and alleviate symptoms of the sleep disorder. The method also considers subjects with atopic disease and those experiencing pain responsive to tactile stimulation, with the treatment aiming to prevent the repetitive occurrence of common migraines. The administration of the pharmaceutical composition can be through injection, including at least two injection sites or multifocal injections, or transdermal administration, with the composition also including a pharmaceutically acceptable carrier for effective delivery.
To know more about GlobalData’s detailed insights on Revance Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
